“…At the same time, such advances have increased patients’ expectations [ 5 , [10] , [11] , [12] ]. That notwithstanding, the impact of these improvements has not always been felt by some populations in emerging economies due to a lack of access to quality healthcare and pharmaceuticals owing to the overall weakness of the public health system [ 13 , 14 ]. More precisely, emerging economies pay 20 times more for life-saving medicines than industrialised economies [ 15 ], provided such medicines are available in the first place.…”